Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

S.      Tangri; C.      LiCalsi; J.      Sidney; A.      Sette

doi:10.2174/0929867023368647

Abstract

One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Keywords: epitope, immunostealth, antibody, htl

Rights & Permissions Print Cite

Current Medicinal Chemistry

Title: Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

Volume: 9 Issue: 24

Author(s): S. Tangri, C. LiCalsi, J. Sidney and A. Sette

Affiliation:

Keywords: epitope, immunostealth, antibody, htl

Abstract: One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Tangri S., LiCalsi C., Sidney J. and Sette A., Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity, Current Medicinal Chemistry 2002; 9 (24) . https://dx.doi.org/10.2174/0929867023368647